Agilent | Trusted AnswersAgilent | Trusted Answers

CQA Analysis for IVT mRNA-Based Biotherapeutics

Agilent application compendium

Page Title | Agilent

IVT mRNA workflows with automated electrophoresis and LC/MS

Critical quality attribute (CQA) assessment is essential in the development of IVT mRNA biotherapeutics to ensure their safety, efficacy, and consistency. Regulatory agencies like the US Pharmacopeia (USP) provide guidelines for evaluating key CQAs, such as identity, content, purity, potency, and safety, throughout the development process. Agilent offers advanced solutions to address these CQAs and help maintain high standards in the IVT mRNA biotherapeutic workflow.

Our comprehensive application compendium features technical overviews and application notes showcasing Agilent automated electrophoresis and LC/MS solutions for reliable CQA assessment throughout the workflow, from DNA starting material to the final drug product.

Contents include:

  • Overviews on the importance of CQA assessment in IVT mRNA biotherapeutic development, with insights into Agilent automated electrophoresis systems and Bio LC solutions.
  • Resources highlighting quality control analysis throughout various stages in the IVT mRNA analysis workflow using Agilent solutions.

Explore how our integrated solutions can support your biotherapeutic development and help you achieve regulatory compliance with confidence.

Claim my copy

For Research Use Only. Not for use in diagnostic procedures. PR7001-3815

Contact us

Contact us for questions about the automated electrophoresis systems.

Your Personal Data

* This field is required

Your Purchase Plan



For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy